Clinical Trial Update: Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer [NA]

View source ↗

Summary

This National Cancer Institute-sponsored clinical trial update reports the completion of a study evaluating Erlotinib in patients with stage IIIB, stage IV, or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | NA | Status: COMPLETED